News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GeoPharma, Inc. (GORX) Reports Success In Clinical Studies On Oral Mucositis Drug For Cancer Patients

10/19/2005 5:08:58 PM

LARGO, Fla., July 13 /PRNewswire-FirstCall/ -- Belcher Pharmaceuticals, Inc, a wholly owned subsidiary of GeoPharma, Inc. , has completed a double blind clinical study to evaluate the efficacy of their patent-pending drug for mucositis in cancer patients. Administration of their drug, MF5232, significantly improved the efficacy parameters with all ratings scales in the patients.

Mucositis is the inflammation of the mucosa in the mouth. It occurs as a side effect of chemotherapy and radiation. According to the National Cancer Institute, oral mucositis occurs in almost all patients receiving radiation for head and neck malignancies, in more than 75 percent of bone marrow transplant recipients, and in nearly 40 percent of patients receiving chemotherapy. Patients with reduced immune response, such as HIV/AIDS may also face this condition. Currently, no effective treatment for mucositis is available. Approximately 400,000 patients in the United States experience mucositis and the market potential is estimated to be at $300 million to $500 million.

"We are excited about the results of this study and we are exploring all the options available to move to the next phase of the development at a faster pace," stated Dr. Kotha Sekharam, Geopharma President and inventor of this drug. "In addition, since the drug is developed with natural ingredients, no side effects are expected."

GeoPharma, Inc. manufactures, packages, repackages and distributes a wide array of health-related products. GeoPharma, Inc. is comprised of the contract manufacturing entity Innovative Health Products and its two wholly owned subsidiaries Belcher Pharmaceuticals and Breakthrough Engineered Nutrition. Innovative Health Products custom-manufactures high-quality nutraceuticals and dietary and other nutritional supplements. Belcher Pharmaceuticals is an FDA- registered plant that manufactures and distributes over-the-counter and generic drugs. Breakthrough Engineered Nutrition markets and distributes its own proprietary line of branded consumer products and convenience foods for the low-carb and low-glycemic lifestyles. Breakthrough's brands, Lean Protein and CarbSlim, are distributed nationwide and are found in both mass retail and specialty outlets. For more about GeoPharma, Inc. go to our websites at, and


Certain oral statements made by management from time to time and certain statements contained in press releases and periodic reports issued by GeoPharma, Inc. (the "Company"), as well as those contained herein, that are not historical facts are "forward-looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, and because such statements involve risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements, including those in Management's Discussion and Analysis, are statements regarding the intent, belief or current expectations, estimates or projections of the Company, its Directors or its Officers about the Company and the industry in which it operates, and are based on assumptions made by management. Forward-looking statements include without limitation statements regarding: (a) the Company's growth and business expansion, including future acquisitions; (b) the Company's financing plans; (c) trends affecting the Company's financial condition or results of operations; (d) the Company's ability to continue to control costs and to meet its liquidity and other financing needs; (e) the declaration and payment of dividends; and (f) the Company's ability to respond to changes in customer demand and regulations. Although the Company believes that its expectations are based on reasonable assumptions, it can give no assurance that the anticipated results will occur. When issued in this report, the words "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," and similar expressions are generally intended to identify forward-looking statements.

Important factors that could cause the actual results to differ materially from those in the forward-looking statements include, among other items, (i) changes in the regulatory and general economic environment related to the health care and nutraceutical industry; (ii) conditions in the capital markets, including the interest rate environment and the availability of capital; (iii) changes in the competitive marketplace that could affect the Company's revenue and/or cost and expenses, such as increased competition, lack of qualified marketing, management or other personnel, and increased labor and inventory costs; (iv) changes in technology or customer requirements, which could render the Company's technologies noncompetitive or obsolete; (v) new product introductions, product sales mix and the geographic mix of sales and (vi) its customers' willingness to accept its Internet platform in the future. Further information relating to factors that could cause actual results to differ from those anticipated is included but not limited to information under the headings "Business," and "Management's Discussion and Analysis of Financial Conditions and Results of Operations" in this Form 10-KSB as of and for the year ended March 31, 2004 which was filed on June 29, 2004. The Company disclaims any intention or obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements which are not historical facts contained in this advertisement are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, governmental approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission

L.G. Zangani, LLC provides financial public relations service to the Company. As such L.G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and or other services in the form of moneys, capital stock in the Company, warrants or options to purchase capital in the Company.

GeoPharma, Inc.

CONTACT: Carol Dore-Falcone, GeoPharma, Inc., +1-727-544-8866, orLeonardo Zangani, L.G. Zangani, LLC, +1-908-788-9660, or,for GeoPharma, Inc.

Read at

comments powered by Disqus